Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
Author:
Funder
F. Hoffmann-La Roche Ltd
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference25 articles.
1. Molecular pathways: ROS1 fusion proteins in cancer;Davies;Clin Cancer Res,2013
2. ROS1-dependent cancers - biology, diagnostics and therapeutics;Drilon;Nat Rev Clin Oncol,2020
3. ROS1 rearrangements define a unique molecular class of lung cancers;Bergethon;J Clin Oncol,2012
4. Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in Caucasian patients: data from a cohort of 713 nonsquamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations;Dugay;Oncotarget,2017
5. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non–small-cell lung cancer;Gainor;JCO Precis Oncol,2017
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer;Lung Cancer;2024-02
2. Entrectinib in the treatment of ROS1-positive lung cancer;Meditsinskiy sovet = Medical Council;2024-01-17
3. Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data;Expert Opinion on Investigational Drugs;2024-01-15
4. Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies;Current Oncology Reports;2024-01-02
5. Clinical Perspectives on the Evolution of Non-small Cell Lung Cancer Treatment With Immuno-oncology and ROS1 Tyrosine Kinase Inhibitors;EMJ Oncology;2023-12-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3